Dendreon to Host Conference Call on February 22 to Announce Fourth Quarter and Full Year 2009 Results

Share Name	Share Symbol	Market	Type
(MM)	NASDAQ:DNDN	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

(MM)

NASDAQ:DNDN

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.1314

01:00:00

Dendreon to Host Conference Call on February 22 to Announce Fourth Quarter and Full Year 2009 Results

11/02/2010 10:00pm

PR Newswire (US)

(MM) (NASDAQ:DNDN)
Historical Stock Chart

From May 2019 to May 2024

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) management will host a conference call on Monday, February 22, 2010 at 4:30 p.m. ET to review fourth quarter and full year 2009 financial results. Access to the discussion may be obtained as follows: Time: 4:30 PM ET / 1:30 PM PT Date: February 22, 2010 Dial-in: 1-800.260.8140 (domestic) or +1-617.614.3672 (international); conference pass code 15732512 Webcast: http://www.dendreon.com/ (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 13123096. The replay will be available from 7:30 pm ET on Monday, February 22 until 11:59 pm ET on Monday, March 1st. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com/. About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon Corporation CONTACT: Katherine Stueland, Vice President, Corporate Communications and Investor Relations of Dendreon Corporation, +1-206-829-1522, Web Site: http://www.dendreon.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

DNDN (MM)